GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evaxion Biotech AS (NAS:EVAX) » Definitions » Quality Rank

EVAX (Evaxion Biotech AS) Quality Rank


View and export this data going back to 2021. Start your Free Trial

What is Evaxion Biotech AS Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Evaxion Biotech AS Quality Rank Related Terms

Thank you for viewing the detailed overview of Evaxion Biotech AS's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Evaxion Biotech AS Business Description

Traded in Other Exchanges
N/A
Address
Dr. Neergaards Vej 5f, Hoersholm, DNK, DK-2970
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.